Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Eliminating 'Sub-Indications' From Inflammatory Bowel Disease Labels

Mar 12 2018

• By Derrick Gingery

Ulcerative colitis endoscopic biopsy

Related Content

<em>Aubagio</em> Approval Reflects FDA’s Evolving View On Multiple Sclerosis Drugs

Mar 19 2013

Pfizer Xeljanz's Long-term Dosing Raises Safety Concerns In Ulcerative Colitis

Mar 07 2018

User Fee Goal Dates

Feb 07 2017

Related Companies

Pfizer Inc.

Johnson & Johnson

Takeda Pharmaceutical Co. Ltd.

Johnson & Johnson

Sanofi Genzyme

Additional Topics

United States Drug Review Review Pathway Regulation FDA Gastrointestinal BioPharmaceutical

More from Product Reviews

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window